Sema4

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Sema4’s mission is to empower individuals and families with a better understanding of their health so they can make informed decisions that improve their lives.

Our vision is to help create a healthier population and to accelerate developments in the field of preventive and personalized medicine. We aspire to be at the forefront of scientific discoveries to improve health and change the way healthcare is delivered.

In 2019, Sema4 was named “Most Innovative Healthcare Company” by the Golden Bridge Awards, and in 2020, the Connecticut Department of Economic and Community Development honored the company with a prestigious Innovation Grant Award.